Equashield (equashield.com), a leading provider of Closed System Transfer Devices (CSTDs) for hazardous drugs, announced today a distribution partnership with Saudi Arabia-based Max Care Medical. Max Care will market and sell Equashield's Closed System Transfer Device for the safe compounding of hazardous drugs in Saudi Arabia, as well as the wider Middle East and North Africa (MENA) region.
"Having been cleared by the Saudi Food and Drug Authority (SFDA), and with registrations recently finalized, there is already market awareness and opportunity of Equashield's products in the region," said Mr. Ibrahim Al Bawardi President and Founder of Max Care Medical.
"Hazardous drug risk awareness has grown in Saudi Arabia. Pharmacists are reading USP 800, and with a majority of our pharmacy and nursing professionals receiving their higher education in Western countries, we are committed to meeting the most stringent safety standards," said Dr. Samer Salha, Executive Director MENA for Max Care Medical. "Further, we are moving into an era of automation. Equashield is already a proven leader in safety with the EQUASHIELD CSTD. The Equashield Pro compounding robot will bring us to the future of safe and efficient robotic hazardous drug compounding."
Max Care will showcase Equashield at two major upcoming regional events: The 5th Annual GCC Pharmacy Congress taking place in Dubai (October 11-13) at Booth 6, as well as the 4th IVPN Symposium(October 16-17), organized by the Cleveland Clinic Abu Dhabi.
Max Care and Equashield will sponsor an educational symposium at the 5th annual GCC Pharmacy Congress. Dr. Manal Al Nemari, R.Ph., CAP, Supervisor of Pharmacy Informatics and Automation at King Fahad Medical City, will present on October 11, at 11:30 a.m. on: "Transforming Pharmacy Practices Through Implementing Robotics: KFMA Experience."
"Max Care Medical is an ideal partner for us. Saudi Arabia has a high level of awareness of hazardous drug hazards, and Max Care is working to educate surrounding MENA markets on the importance of adopting a high level of safe handling standards in accordance with USP 800," said Ronak Kadakia, Director of Marketing for Equashield. "We have already seen growth in the Saudi market, with one of the country's largest hospitals adopting Equashield this year to maintain its accreditation with ASHP standards. This is a trend we expect to continue with other institutions."
-Ends-
About Equashield
Equashield is a leading provider of manual and automated solutions for the compounding and administration of hazardous drugs. Equashield's product suite includes EQUASHIELD II, its flagship Closed System Transfer Device (CSTD), and EQUASHIELD® Pro, the first ever closed system-enabled multi-station hazardous drug compounder. Equashield's CSTD is clinically-proven to protect healthcare professionals from hazardous drug exposure. EQUASHIELD II covers more routes of exposure than alternative systems and has passed the proposed 2015 alcohol vapor containment protocol from NIOSH, confirming that it can contain the harshest vapors & emissions. Studies have shown Equashield's CSTD as faster to deploy and easier to use than competing systems. Used by hundreds of hospitals and clinics around the world, EQUASHIELD II is CE marked and substantiated by the FDA for preventing microbial ingress for up to seven days.
Follow Equashield on LinkedIn, Twitter and Facebook.
For more information: http://www.equashield.com
Media Contact:
Finn Partners for Equashield
Nicole Grubner
nicole.grubner@finnpartners.com
@nicolegrubner
+1-929-222-8011
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
